PREVALENCE OF METABOLIC SYNDROME IN PATIENTS WITH ARTERIAL HYPERTENSION AND ITS IMPACT ON ASYMPTOMATIC CAROTID ATHEROSCLEROSIS

Svetlana Kostic, Ivan Tasic, Dragan Djordjevic, Viktor Stoickov, Nikola Stojanovic

DOI Number
https://doi.org/10.22190/FUMB180424009K
First page
55
Last page
60

Abstract


The importance of metabolic syndrome (MetSy) lies in the fact that its components are proven risk factors for early blood vessel atherosclerosis and thrombosis.Aim of the paper: Our aim was to establish the prevalence of MetSy in patients with arterial hypertension (AH) and its impact on asymptomatic carotid atherosclerosis. The study involved 391 examinees, divided into two groups. The study group consisted of patients with arterial hypertension (n=342; average age, 66.56 ± 09.52; with 51% of female gender). The presence of cardiovascular (CV) risk factors was established for all involved patients, cardiovascular risk score was determined (SCORE risk), laboratory analyses were performed, as well as anthropometric measurements and color Doppler sonography of the great blood vessels of the neck. The patients with AH were divided into two groups according to the presence of MetSy. Metabolic syndrome was confirmed in 198 patients who comprised group I; there were 144 examinees without MetSy and these comprised group II. Those with MetSy had a greater average number of CV risk factors, a higher SCORE risk score, higher body mass index (p<0.0001), and more frequently had diabetes, hyperlipidemia and obesity. The thickness of the intimal medial complex (IMC) of the carotid arteries was significantly greater in the group with MetSy (p<0.0001) – 51% of examinees had IMC thickness ≥0.90. The patients with MetSy more commonly had one or more carotid plaques (p=0.03), a higher average number of plaques (p=0.01) and percentage of stenosis (p=0.01). As the most important factors associated with early carotid atherosclerosis, multivariant regression analysis singled out the following (for the model R=0.512. R2=0.262. adjusted R2=0.255. standard error of the estimate = 0.174; p<0.0001): age (coefficiant β=0.331. p<0.0001), number of MetSy components (coefficient β=0.158. p=0.002), level of serum uric acid (coefficient β=0.284; p<0.0001). Our results demonstrated a significant association of MetSy and its components with early atherosclerotic changes in the carotid arteries.


Keywords

metabolic syndrome, arterial hypertension, asymptomatic carotid atherosclerosis, carotid intima-media thickness, carotid plaque.

Full Text:

PDF

References


Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683–689.

Eckel RH, Grundy SM, Zimmet PZ. The Metabolic Syndrome. Lancet 2005; 365: 1415-1428.

Stern MP, Williams K, Gonzalez-Villalpando C, Hunt KJ, Haffner SM. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care 2004; 27: 2676-2681.

Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult. Treatment Panel III). JAMA 2001; 285: 2486–2497.

Holewijn S, den Heijer M. et al. The Metabolic Syndrome and Its Traits as Risk Factors for Subclinical Atherosclerosis. J Clin Endocrinol Metab, 2009, 94 (8): 2893–2899.

Burke GL, Evans GW, Riley WA, Sharrett AR, Howard G, Barnes RW, Rosamond W, Crow RS, Rautaharju PM, Heiss G, for the ARIC Study Group. Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults. Stroke 1995; 26: 386–391.

Mannami T, Baba S, Ogata J. Strong and significant relationships between aggregation of major coronary risk factors and the acceleration of carotid atherosclerosis in the general population of a Japanese city. Arch Intern Med 2000; 160: 2297–2303.

Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu CR, Liu CH, Azen SP. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998; 128: 262–269.

Jusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, Lang CC,Rumboldt Z, Onen CL, Lisheng L, Tanomsup S, Vangai PJr, Razak F, Sharma AM, Anand SS; INTERHEART Study Investigationi. Obesity and the risk of myocardial infarction in 27.000 participans from 52 countries: a case-control study. Lancet 2005;366 (9497): l640-1649.

Ervin RB. Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003-2006. Natl Health Stat Report 2009; 13: 1-7.

Giuseppe Schillaci, Matteo Pirro, Gaetano Vaudo et al. Prognostic Value of the Metabolic Syndrome in Essential Hypertension. J Am Coll Cardiol 2004; 43:1817–1822.

Marjani A, Mojerloo M. The metabolic syndrome in type 2 diabetic subjects in Gorgan, Iran. J Pak Med Assoc. 2011;61(5):458-461.

Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration, Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010; 375: 1634–1639.

Athyros VG, Ganotakis ES, Bathianaki M, Monedas I, Goudevenos IA, Papageorgiou AA, Papathanasiou A, et al. Awareness, treatment and control of the metabolic syndrome and its components: a multicentre Greek study. Hellenic J Cardiol. 2005;46(6):380-386.

Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am. 2004;33(2): 351-375.

Deibert P, Konig D, Vitolins MZ, Landmann U, Frey I, Zahradnik HP, Berg A. Effect of a weight loss intervention on anthropometric measures and metabolic risk factors in pre - versus postmenopausal women. Nutr J. 2007; 6:31.

Marjani A. A Review on Metabolic Syndrome. J Endocrinol Metab. 2012; 2 (4-5): 166-170.

Hu G, Qiao Q, Tuomilehto J et al for the DECODE Study Group. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004;164:1066-1076.

Lakka HM, Laaksonen DE, Lakk TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-2716.

Butler J, Rodondi N, Zhu Yet. al. The Health, Aging, and Body omposition Study (Health ABC study). Metabolic Syndrome and the Risk of Cardiovascular Disease in Older Adults. J Am Coll Cardiol 2006; 47: 1595–1602.

Lopes NH, Paulitsch FS, Pereira AC, et al. Impact of metabolic syndrome on the outcome of patients with stable coronary artery disease: 2-year follow-up of the MASS II study. Coron Artery Dis. 2008;19:383.

Piepoli M, Hoes A, Agewall S et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). European Heart Journal 2016; 37: 2315–2381.

Petrović B. Bolesti arterija vrata. Akademska misao. Beograd. 2000; 18-23.

Folsom AR, Kronmal RA, Detrano RC, et al. Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence: the Multi-Ethnic Study of Atherosclerosis (MESA). Arch Intern Med. 2008;168:1333-1339.

Holewijn S, den Heijer M, Swinkels DW, et al. The metabolic syndrome and its traits as risk factors for subclinical atherosclerosis. J Clin Endocrinol Metab. 2009;94:2893-2899.

Jobien K. Olijhoeka, Yolanda van der Graaf, Jan-Dirk Banga, Ale Algra et al., for the SMART Study Group. The Metabolic Syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm. European Heart Journal (2004) 25, 342–348.

Petrović B. Bolesti arterija vrata. Akademska misao. Beograd. 2000; 56-64.

Honda O, Sugiyama S, Kugiyama K, Fukushima H, Nakamura S, Koide S, Kojima S, Hirai N, Kawano H, Soejima H, Sakamoto T, Yoshimura M, Ogawa H. J Am Coll Cardiol. Echolucent carotid plaques predict future coronary events in patients with coronary artery disease. J Am Coll Cardiol. 2004; 43(7): 1177-1184.

Khoury Z, Schwartz R, Gottlieb S, Chenzbraun A, Stern S and Keren A. Relation of Coronary Artery Disease to Atherosclerotic Disease in the Aorta, Carotid, and Femoral Arteries Evaluated by Ultrasound. Am J Cardiol 1997; 80: 1429-1433.

Yoichi Inaba, Jennifer A. Chen, Steven R. Bergmann. Carotid plaque, compared with carotid intima-media thickness, more accurately predicts coronary artery disease events: A meta-analysis. Atherosclerosis 2012;220:128–133.




DOI: https://doi.org/10.22190/FUMB180424009K

Refbacks

  • There are currently no refbacks.


ISSN 0354-2017 (Print)

ISSN 2406-0526  (Online)